Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by carduon Nov 12, 2011 11:33am

280 Views

Post# 19232208

Reiteration

I hope this is the trial he's postulating about.

"An interesting post from Raging Bull!

There is some resilience in ONCY if you have been watching. Were it not for this bear, and an especially big bear in small cap/biotech/high beta, I think ONCY would be making new highs. I shouldn't tell, but I have actually added recently. My moles tell me that at least one of the trials currently working with a decent sized cohort is having tremendous success."

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row